Idexx Laboratories (IDXX) Earnings Dates, Call Summary & Reports

Compare

2,142 Followers

Earnings Data

Report Date

May 06, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

3.43

Last Year’s EPS

2.96

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 8 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 02, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a strong operating performance with double-digit organic growth, record instrument placements, meaningful margin expansion, robust free cash flow and aggressive buybacks, and clear commercial and product momentum (InVue DX, CancerDx, Catalyst menu expansions, and software ARR growth). Headwinds include persistent weakness in same-store clinical visits (especially wellness), a decline in rapid assay revenues due to product transition, some instrument-revenue lapping and mix effects, and moderation in pricing. Overall, the positives (revenue/margin growth, cash generation, product commercialization and international strength) outweigh the cited challenges, and management provided constructive 2026 guidance that incorporates known headwinds.

Company Guidance

IDEXX's 2026 guidance calls for full‑year revenue of $4.632–$4.72 billion (reported growth 7.6%–9.6%, organic 7%–9%), CAG Diagnostics recurring revenue organic growth of 8%–10% (≈100 bps improvement at midpoint vs. 2025), and an approximate 60 bps foreign‑exchange tailwind to revenue; management expects ~4% global net price realization (≈3.5% in the U.S.) while assuming roughly a 2% decline in U.S. same‑store clinical visits. The company plans ~5,500 InVue DX placements in 2026, expects CAG instrument revenues to decline as it laps prior rapid placements, and sees reported operating margin of 32%–32.5% (comparable improvement of 30–80 bps year‑over‑year, net of ~30 bps FX benefit and ~20 bps headwind from lapping a litigation accrual). EPS is guided to $14.29–$14.80 (up ~10%–14% on a comparable basis), which reflects $34 million of net interest expense and an FX benefit of about $0.22; the tax rate is expected to be consistent year‑to‑year excluding share‑based compensation. Cash conversion is targeted at 85%–95% of net income with capital expenditures of $180 million (~4% of revenue) and share repurchases intended to reduce diluted shares 1%–2% while maintaining leverage ratios; a 1% change in the U.S. dollar is estimated to move full‑year revenue by ≈$16 million and operating income by ≈$5 million. For Q1, IDEXX expects reported revenue growth of 11.5%–13.5% (≈2.5% FX benefit), organic growth of 9%–11% (including ~1%–1.5% benefit from CAG instrument revenues), Q1 CAG recurring growth of 8.5%–10.5% (≈50 bps days benefit), and reported operating margins of 31.4%–31.9% (net of ~90 bps headwind from lapping prior litigation accrual and ~30 bps FX benefit).

Strong Top-Line Growth

Q4 revenue increased 14% reported and 12% organically; full-year 2025 organic revenue growth was 10%. CAG Diagnostics recurring revenues grew 10% organically in Q4 and 8% organically for the full year. US CAG recurring revenues rose 9% organically in Q4, driven by ~4% net price improvement and ~5% volume growth.

Record Premium Instrument Placements and Installed Base Expansion

Q4 placements of premium instruments totaled 6,567, up 42% year-over-year; full-year placements were ~22,500. InVue DX placements were nearly 6,400 for the year. Global premium instrument installed base expanded ~12% year-over-year and the Catalyst installed base reached ~78,000 units.

Strong Profitability and Cash Generation

Full-year operating margin was 31.6%, up 90 basis points on a comparable basis. Q4 operating profit grew 21% reported (17% comparable). Q4 EPS was $3.08 (+17% comparable) and full-year EPS was $13.08 (+14% comparable). Free cash flow for 2025 was $1.1 billion (100% of net income). The company repurchased $1.2 billion of shares (2.4M shares) and reduced diluted shares outstanding by 2.7% year-over-year.

Meaningful Product Innovation and Commercial Momentum

Multiple launches and expansions (InVue DX, CancerDx, Catalyst Cortisol, Catalyst pancreatic lipase, advanced radiography system) materially contributed to adoption and economic value. InVue DX instrument revenue contributed over $75 million in 2025 and supported roughly 200 basis points of company growth. CancerDx reached nearly 6,000 customers and will add mast cell tumor detection mid-2026.

Recurring Software and SaaS Momentum

Cloud-based PIMs and other software delivered double-digit recurring revenue growth in Q4. Velo users grew ~40% sequentially and nearly tripled year-over-year. The company closed the year with record quarterly bookings and growing ARR, supporting cross-sell and higher utilization.

Reference Lab and International Strength

Global reference lab revenues expanded 9% organically in Q4, aided by volume growth and competitive submissions (~18%). International CAG Diagnostics recurring revenue grew 12% organically in Q4, with strong international instrument growth and double-digit international consumable gains.

Confident 2026 Financial Outlook

Full-year 2026 guidance: revenue $4.632B–$4.72B (+7.6%–9.6% reported; 7%–9% organic), CAG Diagnostics recurring revenue growth targeted at 8%–10% organic, reported operating margin guidance 32%–32.5%, EPS $14.29–$14.80 (10%–14% comparable), and free cash flow conversion outlook of 85%–95% of net income.

Idexx Laboratories (IDXX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IDXX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 06, 2026	2026 (Q1)	3.43 / -	2.96	―	―	―
Feb 02, 2026	2025 (Q4)	2.93 / 3.08	2.62	17.56% (+0.46)
Nov 03, 2025	2025 (Q3)	3.14 / 3.40	2.8	21.43% (+0.60)
Aug 04, 2025	2025 (Q2)	3.30 / 3.63	2.44	48.77% (+1.19)
May 01, 2025	2025 (Q1)	2.85 / 2.96	2.81	5.34% (+0.15)
Feb 03, 2025	2024 (Q4)	2.40 / 2.62	2.32	12.93% (+0.30)
Oct 31, 2024	2024 (Q3)	2.68 / 2.80	2.53	10.67% (+0.27)
Aug 06, 2024	2024 (Q2)	2.88 / 2.44	2.67	-8.61% (-0.23)
May 01, 2024	2024 (Q1)	2.71 / 2.81	2.55	10.20% (+0.26)
Feb 05, 2024	2023 (Q4)	2.12 / 2.32	2.05	13.17% (+0.27)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IDXX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 02, 2026	$670.46	$639.60	-4.60%
Nov 03, 2025	$629.51	$722.94	+14.84%
Aug 04, 2025	$535.54	$682.78	+27.49%
May 01, 2025	$432.65	$471.38	+8.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Idexx Laboratories (IDXX) report earnings?

Idexx Laboratories (IDXX) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).

What is Idexx Laboratories (IDXX) earnings time?

Idexx Laboratories (IDXX) earnings time is at May 06, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IDXX EPS forecast?

IDXX EPS forecast for the fiscal quarter 2026 (Q1) is 3.43.